JAK2 mutation

JAK2 unmutated erythrocytosis: 2023 update on diagnosis and management #mpnsm https://t.co/SOe1dQAhzG (@smbenlazar)

Monday reading for the vexing erythrocytosis consult JAK2 unmutated erythrocytosis: 2023 update on diagnosis and management https://t.co/v3PRBOqSEN #mpnsm @NatashaSzuber #tefferi @MayoCancerCare @AjHematology (@n_gangat)

PRV Jak-2 mutation Acute Leukemia (@iSuksBlood)

Polycythemia vera/PV Increased platelet count, JAK2 67F mutation, AML (@suefreelance)

This is cool! Polycythemia + Eosinophilia associated with novel JAK2 mutation = JAK2ex13InDel Add this to my differential! JAK2ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera https://t.co/eonM3YsPnt (@AaronGoodman33)

#ASCO22 #leusm Menghrajani: Why aren’t JAKi the new imatinib in JAK2 mutated MPN? JAK-STAT may not be only pathway involved. Adding BCL2i to Rux shows promising results. (@hemedoc)

Very interesting @BloodJournal paper from @RaajitRampal et al looking at leukemic transformation in JAK2/TP53-mutated megakaryocyte/erythroid precursors #mpnsm #leusm https://t.co/zUHhGukRmM (@Anand_88_Patel)

We also report the first patients with PV in whom JAK2 mutation became undetectable after 5 years of #ropeginterferon therapy (5 patients) vs. none with standard treatment, a prerequisite for changing #mpnsm disease natural evolution @LeukemiaJnl 👇 https://t.co/PelUXPZaXp (@jjkiladjian)

Happy to share the 5-years results of the PROUD-CONTI PV study confirming the long-term safety and efficacy of #ropeginterferon and the clear superiority for deeply reducing the JAK2 mutation burden compared to standard therapy @LeukemiaJnl #mpnsm 👉 https://t.co/C5z59aOi5H (@jjkiladjian)

Great summary! @AaronGoodman33 One addition for JAK2 mutation JAK2 R683G = Ph-like ALL (~50% of CRLF2 rearranged ALL, a subset of Ph-like ALL have JAK2 mutation, most commonly R683G, never V617F) And yes JAK fusions can also occur in Ph-like ALL #leusm (@NitinJainMD)

Trial in progress: anti-SLAMF7 elotuzumab in JAK2-mutated myelofibrosis w/ @bose_prithviraj of @MDAndersonNews Watch: 👉https://t.co/A7PG0wSgcn👈 #ASH21 @ASH_hematology #HemOnc #LymSM #LeuSM #MMsm (@VJHemOnc)

#ASH21 #MPNSM Oral session #6. Dr Bing Li @RaajitRampal @rosslevinemd | Wonderful, high-impact work: #BMP2 #SMAD pathway activation in #JAK2/#TP53 mutant MEPs promotes leukemic transformation || #MPNSM #leusm #ASHKudos 👏🏽 (@doctorpemm)

Question for #myeloma community - would u start rev maintenance post asct in someone with positive jak2 mutation in peripheral blood mncs - normal counts @TomBmt133 @SagarLonialMD @Rfonsi1 @szusmani @NBahlis @DrOlaLandgren @DrGarethMorgan1 @VincentRK (@akeithstewart)

Very important project leaded by A. Alvarez Larran: should CALR-mutated ET be managed differently than JAK2-mutated? A new #ELN #EuropeanLeukemiaNet project #mpnsm (@jjkiladjian)

We knew from work of Sir Mel Greaves & colleagues that initiating mutations in childhood leukemias often occur in utero, even outside Down syndrome setting. But to develop an MPN at age 54 from a somatic JAK2 mutation that occurred before age 1 is really extraordinary. /2 #ASH20 (@DavidSteensma)

#ASH20 I agree this was very nice work! And important to stress AND the measurement of growth rate. It is well known JAK2 V617F mutations can occur years before diagnosis so early detection alone is not enough. #MPNsm #leusm (@TaylorJ_MD)

Please experts, help me... are there hematological malignancies where reducing the driver mutation is not clinically beneficial? I'm confused, this is disputed for PV and JAK2 mutation, so finding another example could be helpful... I can also take examples in solid tumors... (@jjkiladjian)

Very interesting, this table by @peters_solange. I just think that B2M and JAK2 mutations need to be considered in NSCLC. Not that rare! Maybe about 10 percent (@CespedesMontse)